Investigation of Biomarkers Associated with Low Platelet Counts in Normal Karyotype Acute Myeloid Leukemia.

ABSTRACT: Acute myeloid leukemia (AML) patients are at risk of bleeding due to disease-related lack of platelets and systemic coagulopathy. Platelets play a role in hemostasis. Leukemic blasts have been shown to alter platelet activation in vitro. Here we investigated biomarkers associated with thrombocytopenia in normal karyotype AML (NK-AML). From The Cancer Genome Atlas database, case-control study was performed between normal karyotype (NK) platelet-decreased AML (PD-AML, platelet count < 100 × 10⁹/L, n = 24) and NK platelet-not-decreased AML (PND-AML, with platelet count ≥ 100 × 10⁹/L, n = 13). Differentially expressed gene analysis, pathway analysis and modelling for predicting platelet decrease in AML were performed. DEG analysis and pathway analysis rev

SUBMITTER: Park CH 

PROVIDER: S-EPMC9320053 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature